Why is Colinz Labs falling/rising?

As of 01-Aug, Colinz Laboratories Ltd is experiencing a decline in its stock price, currently at 43.53, which represents a decrease of 0.88 or 1.98%. The stock has been on a downward trend, losing value for the last nine consecutive days and accumulating a total return of -19.12% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Over the past year, the stock has generated a return of -35.22%, while its profits have decreased by 3%. The company's weak long-term fundamentals, including a -2.96% CAGR growth in net sales over the last five years and a low return on equity of 4.40%, further contribute to its negative performance. In the broader market context, Colinz Laboratories Ltd has underperformed compared to the Sensex, which has seen a decline of only 1.06% over the past week. The pharmaceuticals and drugs sector, in which Colinz operates, has also faced challenges, falling by 3.1%. Despite a recent increase in investor participation, with delivery volume rising significantly, the overall sentiment remains negative due to the company's poor financial health and lack of profitability. This combination of factors has led to a significant decline in the stock price, reflecting broader concerns about the company's future performance.